Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:MPH NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMPHMedicureC$1.09-0.9%C$1.10C$0.63▼C$1.33C$11.38M1.0216164,087 shs125 shsRZLTRezolute$9.18+3.6%$7.97$2.21▼$9.88$833.35M0.041.01 million shs1.34 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMPHMedicure0.00%-0.91%-0.91%-12.80%+23.86%RZLTRezolute-1.66%+5.23%+15.06%+50.68%+81.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMPHMedicureC$1.09-0.9%C$1.10C$0.63▼C$1.33C$11.38M1.0216164,087 shs125 shsRZLTRezolute$9.18+3.6%$7.97$2.21▼$9.88$833.35M0.041.01 million shs1.34 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMPHMedicure0.00%-0.91%-0.91%-12.80%+23.86%RZLTRezolute-1.66%+5.23%+15.06%+50.68%+81.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMPHMedicure 0.00N/AN/AN/ARZLTRezolute 2.88Moderate Buy$14.5058.04% UpsideCurrent Analyst Ratings BreakdownLatest RZLT, SCLP, and MPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025RZLTRezoluteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025RZLTRezoluteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/22/2025RZLTRezoluteGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.009/18/2025RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.009/18/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$12.009/18/2025RZLTRezoluteBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.009/3/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMPHMedicureC$23.20M0.49C$0.44 per share2.49C$1.91 per share0.57RZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMPHMedicure-C$2.03M-C$0.13N/A∞N/A-9.65%-10.18%-5.63%N/ARZLTRezolute-$74.41M-$0.97N/AN/AN/AN/A-65.03%-58.86%11/6/2025 (Estimated)Latest RZLT, SCLP, and MPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q1 2026RZLTRezolute-$0.27N/AN/AN/AN/AN/A9/17/2025Q4 2025RZLTRezolute-$0.23-$0.26-$0.03-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMPHMedicureN/A2.24%N/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMPHMedicure4.652.031.29RZLTRezoluteN/A14.3714.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMPHMedicure4.85%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipMPHMedicure26.68%RZLTRezolute14.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMPHMedicureN/A10.44 millionN/ANot OptionableRZLTRezolute4090.83 million77.40 millionOptionableRZLT, SCLP, and MPH HeadlinesRecent News About These CompaniesRezolute (NASDAQ:RZLT) Hits New 1-Year High - Time to Buy?1 hour ago | marketbeat.comRezolute to Participate in Upcoming Investor ConferencesOctober 15, 2025 | globenewswire.comRezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 9, 2025 | globenewswire.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Rezolute (NASDAQ:RZLT)October 9, 2025 | marketbeat.comRezolute, Inc. ($RZLT) CEO 2025 Pay RevealedOctober 7, 2025 | quiverquant.comQRezolute (NASDAQ:RZLT) Sets New 1-Year High - Still a Buy?October 2, 2025 | marketbeat.comCantor Fitzgerald Weighs in on Rezolute FY2026 EarningsOctober 1, 2025 | marketbeat.comWe're Not Very Worried About Rezolute's (NASDAQ:RZLT) Cash Burn RateSeptember 29, 2025 | finance.yahoo.comRezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of "Buy" from AnalystsSeptember 28, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Stock Price Up 7.6% - Still a Buy?September 26, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Reaches New 52-Week High - Still a Buy?September 25, 2025 | marketbeat.comGoldman Sachs Group Inc. Invests $685,000 in Rezolute, Inc. $RZLTSeptember 25, 2025 | marketbeat.comRezolute's (RZLT) "Buy" Rating Reiterated at GuggenheimSeptember 22, 2025 | marketbeat.comWhat is Wedbush's Forecast for Rezolute Q3 Earnings?September 22, 2025 | marketbeat.comHC Wainwright Estimates Rezolute's Q1 Earnings (NASDAQ:RZLT)September 22, 2025 | marketbeat.comRezolute price target raised to $20 from $15 at MaximSeptember 19, 2025 | msn.comRezolute, Inc.: Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business UpdateSeptember 18, 2025 | finanznachrichten.deRezolute, Inc. Reports Fiscal 2025 Financial ResultsSeptember 17, 2025 | tipranks.comRezolute reports Q4 EPS (26c), consensus (23c)September 17, 2025 | msn.comRezolute, Inc. Reports Q4 and Full Year Fiscal 2025 Financial Results and Updates on Ersodetug Development ProgressSeptember 17, 2025 | quiverquant.comQRezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business UpdateSeptember 17, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRZLT, SCLP, and MPH Company DescriptionsMedicure CVE:MPHC$1.09 -0.01 (-0.91%) As of 10/17/2025Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.Rezolute NASDAQ:RZLT$9.18 +0.32 (+3.56%) As of 12:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
